BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21701232)

  • 1. A high proliferative index of recurrent melanoma is associated with worse survival.
    Tu TJ; Ma MW; Monni S; Rose AE; Yee H; Darvishian F; Polsky D; Berman RS; Shapiro RL; Pavlick AC; Mazumdar M; Osman I
    Oncology; 2011; 80(3-4):181-7. PubMed ID: 21701232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
    Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
    J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
    Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
    Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.
    Ladstein RG; Bachmann IM; Straume O; Akslen LA
    BMC Cancer; 2010 Apr; 10():140. PubMed ID: 20398247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
    Kashani-Sabet M; Nosrati M; Miller JR; Sagebiel RW; Leong SPL; Lesniak A; Tong S; Lee SJ; Kirkwood JM
    Clin Cancer Res; 2017 Nov; 23(22):6888-6892. PubMed ID: 28790109
    [No Abstract]   [Full Text] [Related]  

  • 6. Computer-assisted measurement of primary tumor area is prognostic of recurrence-free survival in stage IB melanoma patients.
    Rosenbaum BE; Schafer CN; Han SW; Osman I; Zhong H; Brinster N
    Mod Pathol; 2017 Oct; 30(10):1402-1410. PubMed ID: 28731044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma.
    Hazan C; Melzer K; Panageas KS; Li E; Kamino H; Kopf A; Cordon-Cardo C; Osman I; Polsky D
    Cancer; 2002 Aug; 95(3):634-40. PubMed ID: 12209757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome.
    Lawrence NF; Hammond MR; Frederick DT; Su Y; Dias-Santagata D; Deng A; Selim MA; Mahalingam M; Flaherty KT; Hoang MP
    J Am Acad Dermatol; 2016 Sep; 75(3):595-602. PubMed ID: 27543214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
    Naffouje S; Naffouje R; Bhagwandin S; Salti GI
    Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of initial stage on metastatic melanoma survival.
    Wilson MA; Zhong J; Rosenbaum BE; Utter K; Moran U; Darvishian F; Polsky D; Berman RS; Shapiro RL; Pavlick AC; Osman I
    Melanoma Res; 2019 Jun; 29(3):281-288. PubMed ID: 31026246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics.
    Luen S; Wong SW; Mar V; Kelly JW; McLean C; McArthur GA; Haydon A
    Am J Clin Oncol; 2018 Jan; 41(1):90-94. PubMed ID: 26325493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification.
    Jurmeister P; Bockmayr M; Treese C; Stein U; Lenze D; Jöhrens K; Friedling F; Dietel M; Klauschen F; Marsch W; Fiedler E; von Laffert M
    J Dtsch Dermatol Ges; 2019 Aug; 17(8):800-808. PubMed ID: 31437373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas.
    Ramsay JA; From L; Iscoe NA; Kahn HJ
    J Invest Dermatol; 1995 Jul; 105(1):22-6. PubMed ID: 7615970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.
    Nodin B; Fridberg M; Jonsson L; Bergman J; Uhlén M; Jirström K
    Diagn Pathol; 2012 Jul; 7():82. PubMed ID: 22805320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and Surgical Outcomes for Pediatric Head and Neck Melanoma.
    Richards MK; Czechowicz J; Goldin AB; Gow KW; Doski J; Goldfarb M; Nuchtern J; Langer M; Beierle EA; Vasudevan S; Gupta D; Parikh SR
    JAMA Otolaryngol Head Neck Surg; 2017 Jan; 143(1):34-40. PubMed ID: 27607058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maspin expression and melanoma progression: a matter of sub-cellular localization.
    Martinoli C; Gandini S; Luise C; Mazzarol G; Confalonieri S; Giuseppe Pelicci P; Testori A; Ferrucci PF
    Mod Pathol; 2014 Mar; 27(3):412-9. PubMed ID: 24030740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China.
    Hao M; Zhao G; Du X; Yang Y; Yang J
    Tumour Biol; 2016 Aug; 37(8):10339-48. PubMed ID: 26846098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
    Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
    Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased shedding of HU177 correlates with worse prognosis in primary melanoma.
    Hamilton HK; Rose AE; Christos PJ; Shapiro RL; Berman RS; Mazumdar M; Ma MW; Krich D; Liebes L; Brooks PC; Osman I
    J Transl Med; 2010 Feb; 8():19. PubMed ID: 20178639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients.
    Saiag P; Aegerter P; Vitoux D; Lebbé C; Wolkenstein P; Dupin N; Descamps V; Aractingi S; Funck-Brentano E; Autier P; Dragomir M; Boniol M
    J Natl Cancer Inst; 2015 Dec; 107(12):djv264. PubMed ID: 26376687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.